Uncategorized

Garijo starts as Sanofi CEO with window to ease reliance on Dupixent

Published

on

The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on its cornerstone immunology product.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version